Across the past 12 months, Foghorn Therapeutics insiders reported no open-market purchases or sales.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Adrian Gottschalk | Chief Executive Officer | 0 | 511,704 | 511,704 | 70.7% | 13 Apr, 2026 |
| 2 | Steven F. Bellon | Chief Scientific Officer | 101,957 | 0 | 101,957 | 14.1% | 11 Sep, 2024 |
| 3 | Fanny Cavalie | Chief Strategy/Bus Ops Officer | 75,992 | 0 | 75,992 | 10.5% | 12 Mar, 2024 |
| 4 | Simba Gill | Director | 34,061 | 0 | 34,061 | 4.7% | 14 Sep, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 24 Jun, 2026 | Scott Biller | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Simba Gill | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Ian F Smith | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Stuart Duty | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Michael Mendelsohn | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | B Lynne Parshall | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Thomas J. Jr. Lynch | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Neil Gallagher | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Douglas G. Cole | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 09 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Disposed G | 47,497 | $0.00 | $0 | 0 | Indirect |
| 09 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Acquired G | 47,497 | $0.00 | $0 | 211,704 | Indirect |
| 10 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Disposed G | 59,208 | $0.00 | $0 | 240,792 | Indirect |
| 10 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Acquired G | 59,208 | $0.00 | $0 | 270,912 | Indirect |
| 23 Feb, 2026 | Ryan D Maynard | Chief Financial Officer | Acquired A | 400,000 | $5.75 | $2.30Mn | 400,000 | Direct |
| 05 Feb, 2026 | Adrian Gottschalk | Chief Executive Officer | Acquired A | 1,075,000 | $5.23 | $5.62Mn | 1,075,000 | Direct |
| 30 Jan, 2026 | Carlos Costa | Chief People Officer | Acquired A | 230,000 | $5.71 | $1.31Mn | 230,000 | Direct |
| 30 Jan, 2026 | Steven F. Bellon | Chief Scientific Officer | Acquired A | 300,000 | $5.71 | $1.71Mn | 300,000 | Direct |
| 30 Jan, 2026 | Michael Lacascia | Chief Legal Officer | Acquired A | 295,000 | $5.71 | $1.68Mn | 295,000 | Direct |
| 30 Jan, 2026 | Anna Rivkin | Chief Business Officer | Acquired A | 165,000 | $5.71 | $942.15K | 165,000 | Direct |
| 30 Jan, 2026 | Alfonso Quintas Cardama | Chief Medical Officer | Acquired A | 300,000 | $5.71 | $1.71Mn | 300,000 | Direct |